Tagged with Biotech,

China The latest from Chinese pharma, with dealmaking continuing apace. Featured this week are Zai Lab’s latest IPO listing in Hong Kong, InventisBio Series D financing round for small-molecule drugs, as well as Bioduro and Sundio’s merger to create one of the largest CRDMOs with operations in China and the US.…

China While the vast majority of the global pharma market still comprises small molecule drugs, the biologics sector has grown rapidly since its inception in the 1980s, and presently, biologics represent a stunning eight out of the top ten best-selling drugs in 2019. In China, this sector has lagged behind developed…

China Since the Chinese biopharma boom started in the late-2000s, Chinese biotechs have seen in-licensing as a shortcut to establishing their own portfolios and developing clinical development capabilities, kickstarting their growth. With most of the founding teams having returned from extensive careers in the US and the unparalleled innovation potential of…

USA With US still the reigning global champion in biotech innovation, the dynamic and vibrant biopharma ecosystem in the world’s largest healthcare market continues to churn out ground-breaking innovations with companies aspiring to follow in the footsteps of success stories like Regeneron, Celgene, and Amgen. Once US biotechs achieve the significant…

Korea Joong Myung Cho of Korean biotech success story CrystalGenomics introduces the company’s unique drug discovery platform, key growth factors, highly promising R&D pipeline, and internationalisation plans.   We were the first Korean biotech to have independently developed, commercialized, marketed and exported an innovative drug Dr Cho, could you start by…

USA Karyopharm Therapeutics’ Dr Michael G. Kauffman outlines the genesis of the company he co-founded with his wife, the approval journey of key product XPOVIO®, his ambitious internationalisation plans, and the challenges of being a biotech entrepreneur.   From my experience, many great ideas actually come from people unconstrained by the…

China The latest from Chinese pharma, including a setback for CanSinoBIO’s Canadian COVID-19 vaccine trial, Bayer’s new Beijing manufacturing plant, and biotech Antengene’s potential USD 200 million IPO in Hong Kong.   Canada scraps COVID-19 vaccine trial with Chinese CanSinoBIO https://globalnews.ca/news/7302041/canada-china-covid-19-vaccine-trials-abandoned-national-research-council/ Canada has decided to cancel a coronavirus vaccine development agreement…

China Dr Kerry Blanchard explains why he took on the challenge of becoming CEO of Chinese biotech Everest Medicines and how Everest’s internationalist approach to teambuilding helps it stand out from the crowd in China. He also touches on commercialization, partnerships, funding, and the evolution of the Chinese biopharma landscape.  …

China Founded in 2009 by CEO Dr XU Ting, Alphamab started its journey as a protein engineering company with the ultimate dream of becoming, as many Chinese biotechs aspire, a global biotech company producing world-class innovations. To learn more about some of China’s most innovative and inspirational biotech stories, download our…

Roundup A roundup of the latest news from Chinese pharma, including Big Pharma players losing out in the latest round of domestic procurement bidding, updates on Sinopharm’s experimental COVID-19 vaccine, biotech funding news, and Bayer and Hua Medicine’s diabetes collaboration.   Eli Lilly, Pfizer, Merck among Big Pharma losers in China’s…

China The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment in 2017 at a pace that would seem to outpace the fast-moving China biotech industry.   [Post-merger], I-Mab became an…

China Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines his strategy for the company moving forward.   We believe, to make a meaningful impact on treatment, it is necessary…